Physician profile
Rupinder Singh
NPI 1437464476
$618.16
in general payments reported to CMS, 2019-2025
12 companies · $50.72 in 2025
The $50.72 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.99 · 2020: $31.05 · 2021: $46.12 · 2022: $153 · 2023: $226 · 2024: $45.69 · 2025: $50.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $182.12 | 2023-2024 | Speedicath |
| Urovant Sciences INC | $130.47 | 2022 | |
| Sumitomo Pharma America, INC. | $61.33 | 2023-2025 | Gemtesa |
| Abbvie INC. | $46.12 | 2021 | |
| Boston Scientific Corporation | $41.68 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Hollister Incorporated | $29.94 | 2025 | Infyna Chic, Vapro Plus Pocket |
| Acell, INC. | $28.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.70 | 2019 | |
| Ambu INC. | $22.34 | 2022 | |
| 180 Medical, INC. | $19.09 | 2023 | Speedicath |
| Neotract INC. | $19.08 | 2020 | |
| Astellas Pharma US INC | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.